The drivers for enhancing the screening collection
The changing pattern of drug discovery
The move from pharmacology to screening
The identification of many new disease-linked screening targets
Development of automated screening systems
The evolution of HTS & the race for new leads
There is a need for a significant collection of appropriate molecules for screening